Solid Biosciences (NASDAQ:SLDB – Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect Solid Biosciences to announce earnings of ($0.37) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.
Solid Biosciences (NASDAQ:SLDB – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08. On average, analysts expect Solid Biosciences to post ($1.66) EPS for the current fiscal year and ($1.70) EPS for the next fiscal year.
Solid Biosciences Price Performance
NASDAQ:SLDB opened at $6.20 on Friday. Solid Biosciences has a 1 year low of $3.79 and a 1 year high of $11.45. The stock’s fifty day moving average price is $7.81 and its two-hundred day moving average price is $7.64. The company has a market cap of $664.76 million, a P/E ratio of -3.25 and a beta of 2.47.
Analyst Upgrades and Downgrades
SLDB has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, October 15th. Loop Capital set a $25.00 target price on Solid Biosciences in a research note on Monday, September 14th. Royal Bank Of Canada started coverage on Solid Biosciences in a report on Wednesday, September 16th. They set an “outperform” rating and a $18.00 target price for the company. UBS Group initiated coverage on Solid Biosciences in a research report on Wednesday, October 14th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Wall Street Zen upgraded Solid Biosciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 4th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.79.
Get Our Latest Stock Analysis on SLDB
Solid Biosciences Company Profile
Solid Biosciences Inc (NASDAQ: SLDB) is a biotechnology company focused on developing gene therapies for neuromuscular and other serious genetic diseases. The company uses adeno-associated virus (AAV) delivery technologies and genetic medicine approaches to develop treatments intended to address the underlying causes of disease.
Its lead investigational program, SGT-003, is being developed as a gene therapy for Duchenne muscular dystrophy, a severe X-linked muscle-wasting disorder. Solid Biosciences also has additional preclinical and clinical programs targeting other neuromuscular conditions, including diseases associated with defects in muscle proteins.
Featured Stories
- Five stocks we like better than Solid Biosciences
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
